UK Says Illumina's $1B Genomic Sequencing Deal Problematic

Law360 (June 18, 2019, 4:51 PM EDT) -- The U.K.'s competition enforcer said Tuesday that DNA-sequencing company Illumina Inc.'s planned $1.2 billion purchase of Pacific Biosciences of California Inc. raises concerns about the supply of gene sequencing systems in the country.

The Competition and Markets Authority completed its initial review of the deal and said it has concerns because the move would eliminate Illumina's most significant competitor for the supply of DNA-sequencing systems globally and in the U.K. If the companies are unable to address the concerns, the CMA said it would refer the merger for an in-depth, Phase 2 investigation.

"Aside from the merging parties, there are limited...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS